Use of a wheat extract for reducing sebum secretion in the skin

Abstract

The invention relates to the non-therapeutic nutricosmetic use of a composition in a form suitable for oral administration comprising a wheat extract in a physiologically acceptable medium. The invention is characterized in that the wheat extract contains 35-40% of triglycerides and diglycerides, 20-30% of glycolipids, 7-10% of phospholipids and 2-4% of ceramides and glycosylceramides, by weight relative to the total weight of the extract, and is used to reduce excessive sebum secretion in the skin of the face.

Description

[0001] USE OF WHEAT EXTRACT TO REDUCE SEBUM SECRETION IN THE SKIN

[0002] TECHNICAL FIELD

[0003] The present invention relates to the field of nutricosmetics, that is to say the field of food supplements used to obtain a benefit for the skin.

[0004] More specifically, the invention relates to a composition in a form suitable for oral administration comprising a wheat extract to reduce excessive sebum secretion in the skin.

[0005] The skin is an organ that covers the surface of the body and forms the interface between the organism and the external environment. Its purpose, among others, is to protect the organism against external aggressions.

[0006] For the purposes of the invention, the skin is not a single element in that its composition differs according to the different areas of an individual's body, namely generally dry areas such as the forearms, wet areas such as under the armpits, oily areas such as the face, or thicker areas such as the soles of the feet.

[0007] If the scalp is considered an extension of the skin, it is notably characterized by the greater presence of sebaceous glands and hair follicles compared to other areas of the skin on the rest of the body, contributing to a particular environment.

[0008] Sebum is a complex mixture of lipids (composed, for example, of 30-50% triacylglycerols / diacylglycerols, 15-30% fatty acids, 12-20% squalene, 26-30% wax esters, 3-6% cholesterol esters, and 1.5-2.5% cholesterol) produced by the sebaceous glands in the dermis. It forms an impermeable film, which contributes to skin hydration and the skin barrier function, and delivers lipophilic antioxidants to the skin surface.

[0009] Sebum is therefore very important in the skin environment, provided that it is present in good quantity and of good quality.

[0010] Excessive sebum production leads to oily skin, and several factors greatly influence its production: hormonal influence, age, sex, ethnic origin, body area, time of day, seasons, and climate.

[0011] In people with oily skin, blemishes, such as pimples, generally appear where sebum is abundant: the face, shoulders, and chest area, including the upper back and the front of the chest. On the face, sebum production is highest in the T-zone (the area with high sebum production, namely the forehead, nose, and chin); it is less intense on the cheeks, upper eyelids, and neck (U-zone). Clinical characteristics of oily skin include a shiny appearance, increased skin thickness, uneven skin texture, enlarged or even clogged pores leading to blackheads, a predisposition to acne, and a dull or uneven complexion.The term "skin texture irregularities" refers to all alterations or heterogeneities of the skin's surface that affect its regularity, smoothness, or tactile and / or visual uniformity. These irregularities can manifest as increased roughness, enlarged pores, disorganized microrelief, scaling, areas of localized dryness, or a loss of suppleness and elasticity resulting in a feeling of uneven texture. Problems associated with oily skin can impact self-esteem and quality of life.

[0012] The difference in sebum production between the T-zone (the area with high sebum production, namely the forehead, nose, and chin) and the U-zone (the area with low sebum production, notably the cheeks) characterizes combination skin. In other words, it is oily in the T-zone (forehead, nose, chin) and dry or normal on the rest of the face.

[0013] PREVIOUS TECHNIQUE

[0014] Considering the composition of the skin, ceramides are particularly known for their use in topical application to improve the integrity and barrier function of the skin, especially in atopic dermatitis or sensitive skin (Wu et al., "(Compromised Skin Barrier and Sensitive Skin in Diverse Populations", J. Drugs Dermatol.

[0015] 2021, 20(4 Suppl): 17-22; Draelos ZD, “The effect of ceramide-containing skin care products on eczema resolution duration, Cutis. 2008, 81 (1): 87-91; and Lynde et al., “A cohort study on a ceramide-containing cleanser and moisturizer used for atopic dermatitis,” Cutis. 2008, 2014, 93(4):207-213).

[0016] It also appears that ceramides (for example, the ceramides and / or glycosylceramides contained in an (oily) wheat extract) are particularly known for oral use (e.g., as a dietary supplement) for:

[0017] - to combat hair or animal hair loss and / or to promote their growth and / or regrowth and / or improve their beauty (shine, softness, strength) and / or improve scalp comfort (EP2821052);

[0018] - to be used in compositions for dietary purposes (hydrating properties) and for food purposes (anti-radical, antioxidant, emulsifying and lubricating properties) (FR2785806);

[0019] - improve skin hydration (desquamation, roughness and redness) to prevent and limit skin damage related to aging and possible use in a skin healing process or reduction of dryness, itching and red spots in atopic dermatitis and during skin inflammation (Boisnic et al., “Polar lipids from wheat extract oil improve skin damages induced by aging: Evidence from a randomized, placebo controlled clinical trial in women and an ex vivo study on human skin explant”, 2019).

[0020] We also know from the publication by Leo et al. ("Effect of Rice (Oryza sativa L.) Ceramides Supplementation on Improving Skin Barrier Functions and Depigmentation: An Open-Label Prospective Study," Nutrients 2022, 14, 2737) that daily (oral) supplementation with rice ceramides for three months significantly improved skin hydration, sebum production, firmness and elasticity, and wrinkle severity in the areas evaluated. In particular, sebum production was significantly improved in the cheek, neck, and arm.

[0021] While the underlying mechanism of sebum production induced by ceramide (rice) supplementation remains unclear, it is thought to be associated with increased ceramide production following ceramide consumption. Ceramides are known to enhance lipid synthesis in sebocyte culture models. Interestingly, sebum production in all three areas examined improved significantly compared to the normal healthy range: from 70 to 180 AU for the cheek, from 55 to 130 AU for the neck, and >6 AU for the arm. Older participants in the study showed more significant changes in sebum production in the cheeks and neck than those in younger age groups. It is most likely their extremely low baseline sebum secretion rate that makes them more susceptible to the effects of ceramide supplementation.

[0022] TECHNICAL PROBLEM

[0023] Considering the above, one problem that the invention aims to solve is to implement a natural product based on a wheat extract, known for its use in particular for skin hydration and hair growth, in a new targeted and effective cosmetic application.

[0024] The invention also aims to provide such a composition which does not cause troublesome side effects and does not alter the hormonal balance of the person concerned.

[0025] Surprisingly and unexpectedly compared to ceramide (rice) supplementation, the wheat extract used according to the invention actually reduces sebum secretion, particularly of facial skin.

[0026] TECHNICAL SOLUTION

[0027] The invention therefore relates to the non-therapeutic nutricosmetic use of a composition in a form suitable for oral administration comprising, in a physiologically acceptable medium, a wheat extract containing 35-40% triglycerides and diglycerides, 20-30% glycolipids, 7-10% phospholipids and 2-4% ceramides and glycosylceramides, by weight of the total weight of the extract, to reduce excessive sebum secretion on the skin of the face.

[0028] BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In this description, unless otherwise specified, it is understood that, when an interval is given, it includes the upper and lower bounds of said interval.

[0030] The invention and its resulting advantages will be better understood upon reading the following description and non-limiting embodiments, with reference to the attached figures in which:

[0031] Figure 1 represents the variation in the amount of sebum on the face, in healthy female volunteers with combination to oily skin after daily supplementation for 90 days of a food supplement based on a composition according to the invention (see example 4).

[0032] Figure 2 represents the rate of change in the amount of sebum between JO and J90 versus placebo (see example 4).

[0033] Figure 3 represents the variations in the skin texture irregularity assessment score compared to JO, in healthy female volunteers with combination to oily skin after daily supplementation for 90 days of a food supplement based on a composition according to the invention versus placebo. f p<0.1, ***p<0.001 compared with the placebo group; CFB = “Change From Baseline” (see example 5).

[0034] Figure 4 shows the changes in pore dilation assessment score compared to baseline (J0) in healthy female volunteers with combination to oily skin after daily supplementation for 90 days with a dietary supplement based on a composition according to the invention versus placebo. *p<0.05 compared with the placebo group; CFB = "Change From Baseline" (see example 5).

[0035] Figure 5 represents the changes in the porphyrin assessment score from day 0 in healthy female volunteers with combination to oily skin after daily supplementation for 90 days with a food supplement based on a composition according to the invention versus placebo. f p<0.1, compared with the placebo group; CFB = “Change From Baseline” (see example 5).

[0036] Figure 6 represents the changes in facial skin sebum levels compared to day 0 in healthy female volunteers with combination to oily skin after daily supplementation for 90 days with a food supplement based on a composition according to the invention versus placebo. f p<0.1, compared with the placebo group; CFB = “Change From Baseline” (see example 5).

[0037] Figure 7 represents the changes in the skin texture irregularity assessment score compared to day 0, in healthy female volunteers with combination to oily skin and phototype IV-V-VI after daily supplementation for 90 days of a food supplement based on a composition according to the invention versus placebo. f p<0.1, compared with the placebo group. RCFB = "Relative Change From Baseline" (see example 5).

[0038] Figure 8 shows the changes in facial skin sebum level assessment score compared to JO in healthy female volunteers with combination to oily skin and phototypes IV-V-VI after daily supplementation for 90 days with a dietary supplement based on a composition according to the invention versus placebo. *p<0.05 compared with the placebo group; CFB = "Change From Baseline" (see example 5).

[0039] Figure 9 represents the variations in the pore dilation assessment score compared to JO, in healthy female volunteers with combination to oily skin and phototype IV-V-VI after daily supplementation for 90 days of a food supplement based on a composition according to the invention versus placebo; CFB = “Change From Baseline” (see example 5).

[0040] Figure 10 represents the changes in the porphyrin assessment score from J0 in healthy female volunteers with combination to oily skin and phototype IV-V-VI after daily supplementation for 90 days of a food supplement based on a composition according to the invention versus placebo; CFB = “Change From Baseline” (see example 5).

[0041] DESCRIPTION OF IMPLEMENTATION METHODS

[0042] The invention relates to the non-therapeutic nutricosmetic use of a composition in a form suitable for oral administration comprising, in a physiologically acceptable medium, a wheat extract containing 35-40% triglycerides and diglycerides, 20-30% glycolipids and in particular digalactosyldiacylglycerol (DGDG), 7-10% phospholipids and 2-4% ceramides and glycosylceramides, by weight of the total weight of the extract, to reduce excessive sebum secretion on the skin of the face.

[0043] A physiologically acceptable medium is defined as a medium suitable for use in contact with human and animal cells, without toxicity, irritation, undue allergic response and the like, and proportionate to a reasonable benefit / risk ratio.

[0044] The wheat extract preferably used according to the invention contains 55-65% linoleic acid, 15-20% palmitic acid, 10-15% oleic acid, and 3-4% linolenic acid, by weight of the total weight of triglycerides and diglycerides. The wheat extract contains 20-30% glycolipids, primarily digalactosyldiacylglycerol (DGDG), and 25-30% phosphatidylethanolamine, 30-35% phosphatidylcholine, and 30-35% phosphatidylinositol, by weight of the total weight of phospholipids.

[0045] The wheat extract used is an oily extract or a powder of wheat grain endosperm, preferably an oily extract. In particular, the wheat extract may consist of that used in the product LIPOWHEAT®, marketed by the applicant of this application.

[0046] By way of example, the process for preparing wheat extract used according to the invention may include the step of harvesting wheat grains (Triticum aestivum / vulgare), followed by the removal of the bran and germ. Leaching then allows the separation of starch and gluten, and subsequently, by ethanolic extraction of the wheat gluten, the extract is obtained in the form of an oily extract. Optionally, after a second extraction using acetone, the extract is obtained in powder form with the removal of acetone by drying.

[0047] Oral dosage forms can be solid or liquid. Solid oral forms are generally tablets, hard capsules (capsules), soft capsules, sachets containing powder or granules, gums, powders, food supplements, or foods presented, for example, as biscuits. Liquid oral forms are generally oral solutions, syrups, elixirs, oral emulsions, oral suspensions, oral drops, drinks, or instant beverages.

[0048] The composition used according to the invention is preferably administered in the form of a powder, capsule, caplet or emulsion.

[0049] The composition according to the invention can also be incorporated into food supplement formulas where it can be associated with compounds known to those skilled in the art and thus include sulfur amino acids, vitamins, in particular B vitamins, and / or a plant extract, taken alone or in combination.

[0050] Advantageously, the composition used according to the invention further comprises a rosemary extract, preferably an extract of rosemary leaves (Rosmarinus officinalis), comprising in particular carnosic acid and carnosol.

[0051] The composition preferably used according to the invention comprises rosemary extract at a concentration of between 0.01 and 2% by weight of the total weight of the composition, preferably 0.2%.

[0052] The composition used according to the invention is preferably administered daily as a food supplement for a period of at least 30 days (d), preferably 60d or 90d.

[0053] Advantageously, according to a preferred embodiment, the composition used according to the invention is administered at a dose of 350 mg / day, in one or more doses, preferably in a single dose, for example a single dose in the morning with a large glass of water.

[0054] The composition used according to the invention is administered to a subject of phototype I to VI (according to the Fitzpatrick classification), preferably of phototype II to VI, more preferably of phototype IV to VI. By subject, we mean any healthy person, who therefore does not have, in particular, atopic dermatitis or skin inflammation, for non-therapeutic nutricosmetic use to reduce excessive sebum secretion on the facial skin.

[0055] The composition according to the invention is used to reduce excessive sebum secretion on the skin of the face, preferably in the T-zone, more preferably on the forehead, chin and / or nose.

[0056] Excessive secretion refers to a natural phenomenon that can be described as hyperseborrhea or seborrhea, linked to an excess production of sebum that can occur at any age and result from several factors (fatigue, stress, diet, hormones, heat, pollution, ...), which gives a shiny appearance to the skin characteristic of combination to oily skin.

[0057] The composition according to the invention is used to have an effect on the T-zone of the face, in areas where sebum production is at its maximum, while it is less intense, for example, on the cheeks, upper eyelids and neck.

[0058] Particularly advantageously, the skin on which the composition according to the invention is used is combination or oily skin.

[0059] As mentioned above, oily skin is characterized by a shiny appearance, increased skin thickness, enlarged or even clogged pores leading to blackheads, a predisposition to acne, and a dull or uneven complexion. Problems associated with oily skin can negatively impact self-esteem and quality of life.

[0060] Combination skin is characterized by a difference in sebum production between the T-zone (the area with high sebum production, namely the forehead, nose, and chin) and the U-zone (the area with low sebum production, namely the cheeks). In other words, it is oily in the T-zone (forehead, nose, chin) and dry or normal on the rest of the face.

[0061] The composition according to the invention can also be used to limit excessive sebum secretion in sensitive skin.

[0062] Sensitive skin (or reactive, hyper-reactive, intolerant, or irritable skin) is defined by the appearance of unpleasant sensations such as tightness, tingling, burning (possibly pain or itching) in response to stimuli that would not normally cause such sensations. The contributing factors can be physical, chemical, psychological, or hormonal. These unpleasant sensations cannot be explained by lesions attributable to any skin disease. Thus, although often transient and, in many cases, not accompanied by visible dermatological responses, sensitive skin affects quality of life, and erythema may occasionally occur. The invention, as well as its advantages, will be more easily understood through the examples of embodiments described below.

[0063] EXAMPLES

[0064] Example 1: Composition according to the invention in the form of a softgel capsule (= LIFO WHEAT®)

[0065] Ingredients per capsule Quantity (mg) % Wheat extract according to the invention 349.3 99.8 Rosemary extract 0.7 0.2

[0066]

[0067] Total 350,100.00

[0068] The soft capsule shell is composed of gelatin, glycerol, sorbitol, water and caramel El 50 D.

[0069] This capsule is best taken as a food supplement, preferably at a dosage of 1 capsule per day.

[0070] Example 2: Composition according to the invention in the form of a soft capsule (containing the LIPOWHEAT® product)

[0071] Ingredients per capsule Quantity (mg) % Wheat extract according to the invention 349.3 64.68 Rosemary extract 0.7 0.13

[0072] Borage oil 150 27.78

[0073] beeswax 33 6.11 sunflower lecithin 7 1.30

[0074]

[0075] Total 540,100.00

[0076] The soft capsule shell is composed of gelatin, glycerol, sorbitol and water.

[0077] This capsule is best taken as a food supplement, preferably at a dosage of 1 capsule per day.

[0078] Example 3: Composition according to the invention in the form of a capsule (containing the LIPOWHEAT® product)

[0079] Ingredient(s) per capsule Quantity (mg) % Wheat extract according to the invention 87.325 32.95 Rosemary extract 0.175 0.07 Dicalcium phosphate 162.5 61.32

[0080] Rice flour 15 5.66

[0081]

[0082] total 265,100.00

[0083] The capsule shell is composed of HPMC, coconut powder and calcium carbonate.

[0084] This capsule is best taken as a food supplement, preferably at a dosage of 2 capsules per day.

[0085] Example 4: Evaluation of the effect of a composition according to the invention (example 1 = LIPOWHEAT®) on the modulation of sebum secretion in facial skin

[0086] The objective of this study was to evaluate the effect on facial skin of a food supplement based on a composition according to the invention (example 1, versus placebo) on the modulation of sebum secretion, after 90 days of daily administration at a dose of 350mg (at day 90 compared to day 0 and placebo).

[0087] The study was conducted on 60 healthy female volunteers (58 Caucasian and 2 Asian), aged 20-50, with combination to oily skin.

[0088] Three volunteers withdrew from the study.

[0089] The average age of the remaining 57 volunteers is 42.2 ± 8.6 years.

[0090] 77% of the subjects had combination skin and 23% had oily skin.

[0091] Table 1: Study chronology

[0092] Day 0 Day 30 Day 60 Day 90 Verification of inclusion / non-inclusion criteria X n / year / year / a Informed consent X n / year / year / a Inclusion questionnaire X n / year / year / a 2D photographs (LifeViz Mini) X - - X Sebum level measurement by Sebumeter X - - X Dermatological tolerance check XXXX

[0093]

[0094] Sebum levels were measured at day 0 and day 90 using the MONADERM SKIN DIAGNOSTIC® SM 815 sebumeter (COURAGE & KHAZAKA, Cologne, Germany). Measurements were taken on the forehead, chin, and ala of the nose, and summed for each volunteer to better quantify sebum levels in the T-zone.

[0095] The amount of sebum measured is expressed in g / cm² 2 .

[0096] 2D photographs taken with the LIFEVIZ MINI camera were taken at JO and J90.

[0097] Results

[0098] The variation in the amount of sebum is illustrated by Figure 1.

[0099] Figure 2 particularly highlights the rate of change in the amount of sebum between the amount at JO (TO) and the amount at J90 (T90).

[0100] Table 2:

[0101] Test

[0102] Parameter 1 Parameter 2 P-value Statistical significance

[0103] Lipowheat Lipowheat

[0104] Wilcoxon <0.0001 ****

[0105]

[0106] Placebo T0 Placebo T90 Wilcoxon 0.0764 NS

[0107] rate rate

[0108] Mann- variation variation 0.0004 ***

[0109] Whitney

[0110]

[0111] Lipowheat Placebo

[0112] ***p<0.001, ****p<0.0001, NS: Not Significant

[0113] Conclusion

[0114] A significant decrease in the amount of sebum of 23.4% was observed after 90 days of use of the LIPOWHEAT food supplement (example 1) in 29 subjects, while the placebo did not significantly change the amount of sebum.

[0115] Comparative analysis of JO versus J90 variations in the LIPOWHEAT and placebo groups using the Mann-Whitney test highlights a statistically greater decrease in the amount of sebum in the LIPOWHEAT group compared to the placebo group.

[0116] Example 5: Evaluation of the effect of a composition according to the invention (example 1 = LIPOWHEAT®) on skin texture irregularities, pore dilation, porphyrins, and sebum levels in facial skin

[0117] The objective of this study was to evaluate the effect on facial skin of a food supplement based on a composition according to the invention (example 1), on the modulation of skin texture irregularities, pore dilation, the amount of porphyrins and the sebum level, after 90 days of daily administration at a dose of 350mg (on days 30 and 90 compared to placebo).

[0118] The study is conducted on 60 healthy female volunteers of phototypes II to VI (according to the Fitzpatrick classification), aged 20 to 60, with combination to oily skin.

[0119] The Fitzpatrick classification is a skin typing system based on the skin's reaction to initial sun exposure, assessing the tendency to burn (erythema) and tan (melanogenesis). It comprises six phototypes (I to VI), ranging from very fair skin, which always burns and never tans, to very dark skin, which never burns and tans intensely. This system, widely used in dermatology, relies on self-assessment and has limitations for pigmented skin, justifying the integration of more objective assessment methods.

[0120] Four volunteers withdrew from the study.

[0121] The average age of the remaining 56 volunteers is 37.71 ± 11.19 years.

[0122] 86% of the subjects had oily skin and 14% had combination skin. Phototypes II or III represented 77% of the volunteers and 23% of the volunteers had phototypes IV, V or VI.

[0123] Dermatological tolerance was excellent during the study.

[0124] Table 3: Study chronology

[0125] J0 J30 J90 Verification of inclusion / non-inclusion criteria X n / an / a

[0126]

[0127] Informed consent X n / an / a 2D photography (VISIA CR5) XXX Skin texture assessment via VISIA CR5 XXX Enlarged pore assessment via VISIA CR5 XXX Porphyrin assessment via VISIA CR5 XXX Sebum level measurement via sebumeter XXX Dermatological tolerance check n / a XX

[0128]

[0129] The following parameters were measured:

[0130] Evaluation of skin texture irregularities using 2D photography with VISIA CR5. Skin texture corresponds to raised and recessed areas reflecting variations in the skin surface that affect its smoothness. In oily skin, this texture is quite irregular; evaluation of enlarged pores using 2D photography with VISIA CR5. Pores are circular openings on the surface of the ducts of the sweat and sebaceous glands. They are often more dilated and visible in oily skin;

[0131] Evaluation of porphyrin levels using 2D photography with VISIA CR5. Porphyrins are bacterial excretions that can become lodged in pores. Often present in excess on oily skin, they can cause inflammation and promote the appearance of blemishes such as pimples or blackheads; and

[0132] measurement of sebum levels with the SM 815 sebumeter.

[0133] Skin texture, pore dilation, and porphyrin assessments were performed at 0.00 (inclusion), 30 days, and 90 days using standardized facial photographs taken with the VISIA CR5 2D system (Canfield Scientific Inc., Parsippany, New Jersey, USA).

[0134] During the analysis, several photos of the face are taken under different lighting conditions (standard, polarized, UV, etc.).

[0135] The images reveal both the visible and underlying characteristics of the skin (pores, texture, wrinkles, etc.).

[0136] The results are normalized to provide a score between 0 and 1:

[0137] Close to 0 — indicates good skin condition (few irregularities detected).

[0138] Close to 1 — indicates a more pronounced state compared to the reference database (more irregularities detected).

[0139] The results of the evaluation of skin texture irregularities are presented in Figure 3 and Figure 7.

[0140] The results of the pore dilation assessment are shown in Figure 4 and Figure 9. The results of the porphyrin quantity assessment are shown in Figure 5 and Figure 10.

[0141] The results of the sebum level assessment are presented in Figure 6 and Figure 8.

[0142] Sebum levels were assessed at baseline (day 0), day 30, and day 90 using the MONADERM SKIN DIAGNOSTIC® SM 815 sebumeter (COURAGE & KHAZAKA, Cologne, Germany). Measurements were taken on the forehead, chin, and ala of the nose, and summed for each volunteer to better quantify sebum levels in the T-zone.

[0143] The amount of sebum measured is expressed in g / cm² 2 .

[0144] The final result corresponds to an average of 3 measurements taken over a 2cm area 2 of the cheek.

[0145] The results are presented in Table 4.

[0146] Table 4:

[0147] Placebo type LIPOWHEAT example 1) Parameter

[0148] analysis

[0149] studied J30 J90 J30 J90

[0150] statistical

[0151] -0.0038 ± 0.0011 ± -0.0108 ± -0.0175 ± CFB

[0152] 0.0211 0.0262 0.0231* 0.0296*** Irregularities

[0153] RCFB texture -0.2336 ± 2.9753 ± -4.4026 ± -6.3157 ±

[0154] 9.4091 15.1085 12.1277* 19.0859*** the skin

[0155] Answering machine

[0156] 53.57 39.29 71.43 85.71*** (%)

[0157] -0.0007 ± 0.0035 ± -0.0046 ± -0.0122 ± CFB

[0158] 0.0239 0.0352 0.0165 0.0211* Dilation of 1.4808 ± 12.9384 ± -2.2912 ± -12.2155 ±

[0159] RCFB

[0160] pores 27.0836 42.6315) 22.1377 27.4869*

[0161] Answering machine

[0162] 53.57 42.86 57.14 71.43* (%)

[0163] -0.0008 ± 0.0050 ± -0.0004 ± -0.0493 ± CFB

[0164] 0.1209 0.1304 0.0367 0.0984* 17.7041 ± 29.9532 ± 1.1625 ± -10.5160 ± Porphyrins RCFB

[0165] 89.4002 122.1962 10.2285 38.7657* Answering machine

[0166] 64.29 60.71 57.14 82.14* (%)

[0167] -7.8929 ± -17.1071 ± -8.3214 ± -71.1786 ± CFB

[0168] 60.9780 82.5296 98.6010 115.5666* -2.8505 ± -5.2429 ± -0.1399 ± -15.1842 ± Sebum RCFB

[0169] 16.3050 22.9783 28.4599 26.7483* Answering machine

[0170] 71.43 64.29 46.43 85.71*

[0171]

[0172] (%)

[0173] with ***p<0.001, **p<0.01, *p<0.05, *p<0.1 versus placebo.

[0174] Change From Baseline (CFB) values ​​represent changes relative to the baseline value. They are calculated as follows: value at JX (here, J30 or J90) - value at JO. This is the difference between the measurement at a given time and the measurement at the beginning of the study. Relative Change From Baseline (RCFB) values ​​represent relative changes, expressed as a percentage, relative to the baseline value. They are calculated as follows: [value at JX (here, J30 or J90) - value at JO] value at JO x 100.

[0175] The "responder" designations indicate the percentage of volunteers who showed an improvement in the parameter studied.

[0176] Conclusion

[0177] After just 30 days of supplementation with the LIPOWHEAT food supplement (example 1), a 4.4% improvement in skin texture compared to baseline (T0) was observed, a statistically significant change compared to the placebo group. After 90 days, this improvement increased to 6.3% compared to baseline (T0), with a similarly significant difference compared to the placebo group.

[0178] After 90 days, a decrease in porphyrins of 10.5% and in the amount of sebum of 15.2% compared to T0 was observed, with a trend towards statistical significance compared to the placebo group.

[0179] Pore ​​dilation is reduced by 12.2% compared to T0 after 90 days, this reduction being statistically significant compared to placebo.

[0180] The percentage of responders is statistically higher in the LIPOWHEAT group than in the placebo group for all parameters studied.

[0181] Finally, and surprisingly, in subjects with phototype IV, V or VI, an improvement in skin texture of 11.7% and a reduction in sebum levels of 26.8% compared to T0 were observed after 90 days of supplementation, these variations being statistically significant compared to the placebo group.

Claims

DEMANDS 1. Non-therapeutic nutricosmetic use of a composition in a form suitable for oral administration comprising, in a physiologically acceptable medium, a wheat extract containing 35-40% triglycerides and diglycerides, 20-30% glycolipids, 7-10% phospholipids and 2-4% ceramides and glycosylceramides, by weight of the total weight of the extract, to reduce excessive sebum secretion on the skin of the face.

2. Use according to claim 1, characterized in that the wheat extract contains 55-65% linoleic acid, 15-20% palmitic acid, 10-15% oleic acid, and 3-4% linolenic acid, by weight of the total weight of triglycerides and diglycerides, essentially digalactosyl-diglycerol (DGDG) as glycolipids and 25-30% phosphatidyl-ethanolamine, 30-35% phosphatidyl-choline and 30-35% phosphatidylinositol, by weight of the total weight of phospholipids.

3. Use according to claim 1 or 2, characterized in that the wheat extract is an oily extract.

4. Use according to any one of the preceding claims, characterized in that sebum secretion is reduced in the T-zone, preferably of the forehead, chin and / or nose.

5. Use according to any one of the preceding claims, characterized in that the skin is combination or oily skin.

6. Use according to any one of the preceding claims, characterized in that the composition further comprises a rosemary extract, preferably a rosemary leaf extract (Rosmarinus officinalis).

7. Use according to claim 6, characterized in that the composition comprises rosemary extract at a concentration of between 0.01 and 2% by weight of the total weight of the composition, preferably 0.2%.

8. Use according to any one of the preceding claims, characterized in that the composition is administered in the form of a powder, capsule, caplet, or emulsion.

9. Use according to any one of the preceding claims, characterized in that the composition is administered daily as a supplement food for a period of at least 30 days (d), preferably 60d or 90d.

10. Use according to any one of the preceding claims, characterized in that the composition is administered at a dose of 350 mg / day, in one or more doses.

11. Use according to any one of the preceding claims, characterized in that the composition is administered to a subject of phototype I to VI (according to the Fitzpatrick classification).

12. Use according to the preceding claim, characterized in that the composition is administered to a subject of phototype IV to VI.

Images